
Alexander Kuhlmann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1798426/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Age- and gender-based comorbidity categories in general practitioner and pulmonology patients with COPD. Npj Primary Care Respiratory Medicine, 2022, 32, 17.	2.6	3
2	The Kenevo microprocessor-controlled prosthetic knee compared with non–microprocessor-controlled knees in individuals older than 65 years in Sweden: A cost-effectiveness and budget-impact analysis. Prosthetics and Orthotics International, 2022, Publish Ahead of Print, .	1.0	0
3	Individual social contact data and population mobility data as early markers of SARS-CoV-2 transmission dynamics during the first wave in Germany—an analysis based on the COVIMOD study. BMC Medicine, 2021, 19, 271.	5.5	30
4	Healthcare costs associated with breast cancer in Germany: a claims data analysis. European Journal of Health Economics, 2020, 21, 451-464.	2.8	11
5	Cost-effectiveness and budget impact of the microprocessor-controlled knee C-Leg in transfemoral amputees with and without diabetes mellitus. European Journal of Health Economics, 2020, 21, 437-449.	2.8	12
6	Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions. Pharmacoeconomics, 2019, 37, 1093-1127.	3.3	19
7	Authors' reply to Gandjour: "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany― European Journal of Health Economics, 2018, 19, 473-481.	2.8	1
8	PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study. European Journal of Cancer, 2018, 92, 11-19.	2.8	55
9	Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. European Journal of Health Economics, 2017, 18, 273-292.	2.8	18
10	Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting. BMC Medicine, 2017, 15, 162.	5.5	37
11	The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany. Journal of Pharmaceutical Policy and Practice, 2016, 9, 39.	2.4	3
12	Analysis of contemporary HIV/AIDS health care costs in Germany. Medicine (United States), 2016, 95, e3961.	1.0	13
13	Unemployment, health, and education of HIV-infected males in Germany. International Journal of Public Health, 2016, 61, 593-602.	2.3	24
14	The Role of decision-analytic modelling in German health technology assessments. Health Economics Review, 2015, 5, 7.	2.0	1
15	Impact of radiofrequency ablation for patients with varicose veins on the budget of the German statutory health insurance system. Health Economics Review, 2013, 3, 9.	2.0	7
16	Pneumococcal Vaccination Rates in Adults in Germany. Deutsches Ärzteblatt International, 2013, 110, 743-50.	0.9	30
17	Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Economics Review, 2012, 2, 4.	2.0	29
18	Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study. Applied Research in Quality of Life, 0, , 1.	2.4	1